Kyntra Bio 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Kyntra Bio terminated development of FG3246, a CD46-targeted antibody-drug conjugate, and FG3180, its companion PET imaging agent, after a planned interim analysis of the Phase 2 monotherapy study showed insufficient efficacy to support continued development.
- The Phase 2 study had aimed to improve on the Phase 1 median radiographic progression-free survival of 8.7 months, with a target of at least 10 months at final analysis; Kyntra Bio said the interim results and rising competitive bar made that target challenging in both the all-comers and CD46-enriched populations.
- Kyntra Bio is returning the assets to Fortis Therapeutics and has commenced wind-down activities.
- Kyntra Bio reported 3rd quarter 2026 revenue of $1.8 million, compared with $1.1 million in the same period in 2025; operating costs and expenses were $14.6 million, compared with $6.5 million.
- 3rd quarter 2026 R&D expenses were $8.3 million, compared with $1.2 million in the 3rd quarter of 2025, while SG&A expenses were $5.8 million, compared with $5.3 million.
- Kyntra Bio recorded net income from continuing operations of $0.2 million, or $0.04 per basic and diluted share, compared with a net loss of $13.1 million, or $3.25 per basic and diluted share, 1 year ago; the result included a $14 million gain on debt restructuring.
- As of September 30th, Kyntra Bio reported $44.1 million in cash, cash equivalents, investments, and accounts receivable.
- Under an amended NovaQuest royalty financing agreement, the maximum aggregate payment obligation fell from $125 million to $65 million; Kyntra Bio made an accelerated upfront payment of $42.6 million in the 3rd quarter of 2026, bringing total payments to $50 million, with remaining payments capped at $15 million.
- In the Matterhorn high transfusion burden population, 36% of roxadustat patients achieved at least 8 straight weeks of transfusion independence within the first 28 weeks, versus 7% with placebo; over 52 weeks, the rates were 45% and 13%, respectively.
- In the high transfusion burden subgroup, 36% of roxadustat patients achieved at least 12 weeks of transfusion independence within 52 weeks, versus 7% with placebo, and 18% achieved at least 16 weeks, versus 0% with placebo.
- In the Matterhorn high transfusion burden group, transfusion-independent responses were observed in 38% of RS-negative and 33% of RS-positive patients; in the full analysis set, 48% of RS-negative and 46% of RS-positive roxadustat patients achieved 8-week RBC transfusion independence.
- Among high transfusion burden patients categorized as ESA refractory, 31% of roxadustat-treated patients achieved at least 8 weeks of transfusion independence within 28 weeks, compared with none of the placebo-treated patients.
- In the overall Matterhorn study population, grade 3 or higher treatment-emergent adverse events occurred in 38% of roxadustat patients and 21% of placebo patients; in the high transfusion burden subgroup, the rates were 65% and 27%, while discontinuations due to adverse events were 22% and 20%, respectively.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
I would now like to hand the call over to Gaia Vasiliver-Shamis. Please, go ahead. Thank you, operator.
Good afternoon, everyone. Thank you for joining today to discuss Kyntra Bio's third quarter 2026 financial and business results. I'm Gaia Shames from LifeSci Advisors. Joining me on today's call are Thane Wettig, Chief Executive Officer, David DeLucia, Chief Financial Officer, Dr. Carrie Brownstein, Chief Medical Officer, and Carol Gaddum, Vice President of Product Development. Following the prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about Kyntra Bio. Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, regulatory strategies and potential regulatory results, research and development activities, commercial results and results of operations, risks related to our business, and certain other business matters.
Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Kyntra Bio's filing with the SEC, including our most recent Form 10-K and Form 10-Q. Kyntra Bio does not undertake any obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. The press release reporting the company's financial results and business update and a webcast of today's conference call can be found on the investor section of Kyntra Bio website at www.kyntrabio.com. With that, I would like to turn the call over to CEO Thane Wettig.
Thane? Thank you, Gaia. Good afternoon, everyone, and welcome to our third quarter 2026 earnings call.
On today's call, I will provide important updates on the company's transformation and the direction of Kyntra Bio moving forward, and then David DeLucia, our CFO, will review the financials, after which we will open the call for your questions. Turning to slide three, in the fourth quarter of 2026, the company completed a pre-planned interim analysis of the phase II monotherapy trial of FG-3246, an antibody drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer, and FG-3180, a companion PET imaging agent. Unfortunately, based upon insufficient interim efficacy results that did not meet the threshold required to support continued development, we have made the decision to terminate the phase II study of FG-3246 and FG-3180. I would like to provide context underpinning our decision to terminate the program.
In May of 2023, we entered into the license agreement with Fortis Therapeutics based on the potential of the CD46-targeted ADC and its companion PET imaging agent in mCRPC. In April of 2024, results from the phase I monotherapy study of FG-3246 demonstrated a median radiographic progression-free survival, or rPFS, of 8.7 months in the heavily pretreated population. Our subsequent phase II monotherapy study was designed with the intention to determine whether we could improve upon those results, with a target of at least 10 months of median rPFS at final analysis, a target that was based not only on currently available therapies, but also based on data from products in development. Following the review of data from the planned interim analysis, the efficacy findings do not support continuing to advance the program.
Not only do the data point to a challenging path forward, achieving the minimum of 10 months of median rPFS in both an all-comers population and in a CD46-enriched population, recently disclosed competitive data indicates that the clinical bar is simply getting higher. We therefore made the decision to terminate the development of FG-3246 and FG-3180. As a result of this decision, the company is returning the asset to Fortis and has commenced wind-down activities. In addition, we will save approximately $20 million in planned operating expenses across 2027 and 2028. Clearly, this was not the outcome we had hoped for, and on behalf of Kyntra Bio, I would like to extend our sincere gratitude to the patients and their families, clinical investigators, their research teams, and site personnel, whose commitment and participation made this study possible.
Turning to slide four, we highlight our evolution into a pure-play rare disease company focused on the phase III development of roxadustat for patients with anemia associated with lower-risk myelodysplastic syndrome and high red blood cell transfusion burden, or HTB. Our phase III strategy is informed by the post-hoc results from the MATTERHORN study in the high transfusion burden population and reinforced by input from KOLs and a productive engagement with the FDA on the phase III study design. We believe that there is a substantial unmet need for a new treatment with a novel mechanism of action and oral route of administration that can demonstrate efficacy across the broad spectrum of patients suffering from anemia due to lower-risk MDS.
Additionally, we have transformed the company's balance sheet with the amendment of our NovaQuest royalty financing agreement, which reduced our maximum payment obligation by $60 million and lowered our remaining royalty-backed payment obligations to only $15 million. Our simplified capital structure and current cash balance of over $44 million provides the company a strong financial foundation and the resources to continue to prepare for the initiation of the roxadustat phase III development program. The termination of the FG-3246 and FG-3180 program enables us to concentrate our resources on the defined phase III development plan for roxadustat. We are currently on track to initiate this study in the first quarter of 2027, subject to the execution of either a strategic partnership or an external capital raise. I will discuss our conviction behind this focus and review the clinical evidence and planned phase III trial design in subsequent slides.
Moving on to the roxadustat lower-risk MDS program. Slide six highlights the prevalence and unmet need associated with lower-risk MDS. Approximately 74,000 people in the U.S. are living with MDS, including about 52,000 with lower-risk disease and roughly 41,000 patients diagnosed with anemia, the hallmark symptom and main driver of morbidity of this condition. While additional therapies have become available over the past few years, patients who progress beyond first-line treatment continue to have limited options, as these treatments require in-office injections or infusions with responses that are often not durable. It stabilizes HIF-alpha, mimicking the body's natural response to low oxygen, leading to an increase in hemoglobin. Second, HIF activation stimulates red blood cell production by increasing endogenous erythropoietin, improving iron availability, and supporting red blood cell maturation.
Third, and importantly, HIF activates GATA1, a master. Importantly, roxadustat has been approved in more than 40 countries for anemia associated with chronic kidney disease, demonstrating not only important hemoglobin response, but also significantly fewer transfusions in the CKD patient population. In addition, over 1 million patients have been treated with roxadustat worldwide since its first approval in 2019, reinforcing its efficacy and safety profile. In the following slides, I will provide a detailed review of the post-hoc analysis of patients from our previous phase III MATTERHORN study, with a focus on patients with high transfusion burden using the International Working Group definition of four or more RBC units in two consecutive eight-week periods. We believe these results demonstrate roxadustat's potential as a safe and effective oral treatment option for patients with lower-risk MDS.
Slide eight highlights previously disclosed results in the high transfusion burden population from the MATTERHORN phase III trial, demonstrating that treatment with roxadustat led to transfusion independence in 36% of patients for at least eight straight weeks within the first 28 weeks of the trial, versus only 7% in the placebo group, with a nominal p-value of 0.041. These results are highly similar to the pivotal trial results from the two most recently approved therapies for anemia associated with lower-risk MDS. When we assessed eight-week RBC transfusion independence over 52 weeks in the high transfusion burden population, the corresponding rates were 45% for roxadustat and 13% for placebo, with a highly similar nominal p-value of 0.043. The following slides provide additional supporting data of roxadustat's effect on this high transfusion burden population.
Slide nine shows the potential durability of transfusion independence with treatment of roxadustat versus placebo over extended periods of time. In the high transfusion burden subgroup, 36% of roxadustat patients achieved at least 12 weeks of transfusion independence within 52 weeks, versus only 7% with placebo, and at least 16 weeks of transfusion independence within 52 weeks in 18% of roxadustat-treated patients versus 0% for placebo. On slide 10, when looking at hemoglobin levels over time, which is the underlying basis that enables transfusion independence to be achieved, there was a consistent and meaningful increase in hemoglobin in roxadustat-treated patients versus placebo. Mean hemoglobin on roxadustat rose by approximately 1 gram per deciliter from baseline and was sustained through week 28, while placebo remained near or slightly below baseline. These results reinforce the effect that roxadustat can have in the high transfusion burden patient population.
We then further explored whether roxadustat has the potential to benefit patients regardless of ring sideroblast, or RS, status, which is shown on slide 11. In the MATTERHORN high transfusion burden patient group, we observed transfusion-independent responses in both RS-negative and RS-positive patients, 38% and 33%, respectively. These results were mimicked in the full analysis set, where 48% of RS-negative patients and 46% of RS-positive patients on roxadustat achieved eight-week RBC transfusion independence. This is extremely important as we think about the substantial unmet need in RS-negative patients and the potential placement of roxadustat in the treatment paradigm. I will touch more on this later in the presentation. On slide 12, we assessed patients who had previously received ESA therapy.
Among high transfusion burden patients categorized as ESA refractory, 31% of roxadustat-treated patients achieved at least eight weeks of transfusion independence within 28 weeks, compared with none of placebo-treated patients, with a nominal P-value of 0.040. As you can see, the roxadustat treatment effect versus placebo is more pronounced in the ESA refractory population than in the ESA-naive population. We are highly encouraged by these results, given that ESA refractory high transfusion burden patients from the MATTERHORN study most closely mimic the inclusion criteria for our planned upcoming phase III study. Slide 13 highlights the efficacy of roxadustat in the high transfusion burden population by baseline EPO serum levels. Roxadustat achieved greater eight-week transfusion independence versus placebo in patients with baseline EPO serum levels both below 200 and above 200.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
